Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
| Autor: | Martin Barbeau, Paul Harasymowycz, Catherine Royer, Katherine Jobin-Gervais, Jean Lachaine, Amy Xianying Cui, Catherine Beauchemin, K. Mathurin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Network Meta-Analysis Brinzolamide Timolol 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound Travoprost 0302 clinical medicine Dorzolamide Ophthalmology medicine Humans 030212 general & internal medicine Latanoprost Carteolol Antihypertensive Agents Intraocular Pressure Prostaglandins A Bimatoprost business.industry Tafluprost Bayes Theorem Amides Sensory Systems Betaxolol Unoprostone chemistry Brimonidine Tartrate Prostaglandins F Synthetic 030221 ophthalmology & optometry Ocular Hypertension business Glaucoma Open-Angle medicine.drug |
| Zdroj: | British Journal of Ophthalmology. 106:640-647 |
| ISSN: | 1468-2079 0007-1161 |
| DOI: | 10.1136/bjophthalmol-2020-317262 |
| Popis: | Background/aimsTo assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP).MethodsA systematic literature review adapted from the Li et al (Ophthalmology, 2016) study was conducted. Medline, Embase and PubMed were searched for randomised controlled trials published between 1 January 2014 and 19 March 2020. Studies had to report IOP reduction after 3 months for at least two different treatments among placebo, PGAs (bimatoprost 0.01%, bimatoprost 0.03%, latanoprost, LBN, tafluprost, unoprostone) or apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide, levobunolol, timolol, travoprost. A Bayesian network meta-analysis was performed to provide the relative effect in terms of mean difference (95% credible interval) of IOP reduction and ranking probabilities. Surface under the cumulative ranking curve (SUCRA) was generated.ResultsA total of 106 trials were included with data for 18 523 participants. LBN was significantly more effective than unoprostone (−3.45 (−4.77 to −2.12)). Although relative effect was not significative, compared with other PGAs, LBN numerically outperformed latanoprost (−0.70 (−1.83 to 0.43)) and tafluoprost (−0.41 (−1.87 to 1.07)), was similar to bimatoprost 0.01% (-0.02(−1.59 to 1.55)) and was slightly disadvantaged by bimatoprost 0.03% (−0.17 (−1.42 to 1.07)). LBN was significantly more efficient than the beta-blockers apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide and timolol. According to SUCRA, LBN was ranked second after bimatoprost 0.03%, followed by bimatoprost 0.01%.ConclusionLBN was significantly more effective than the PGA unoprostone and most of the beta-blockers. Compared with the most widely used PGAs, LBN numerically outperformed latanoprost and travoprost and was similar to bimatoprost 0.01%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|